Clinical Trial Update: Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of Bryostatin-1 in patients with recurrent non-Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Bryostatin-1 (bryostatin-1)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lymphoma | Phase 2 | Status: COMPLETED